Literature DB >> 25659876

A novel multivariate scoring system for determining the prognosis of lymph node-negative esophageal squamous cell carcinoma following surgical therapy: an observational study.

G Ma1, X Zhang1, Q Ma1, T Rong1, H Long1, P Lin1, J Fu2, L Zhang3.   

Abstract

BACKGROUND: Identifying patients with esophageal squamous cell carcinoma (ESCC) with negative prognostic factors, which have an extremely low survival rate, has been problematic.
METHODS: We retrospectively collected clinical data for 648 patients with lymph node-negative ESCC who were treated at the Sun Yat-Sen University Cancer Center from 1990 to 2005. Survival difference was compared using Kaplan-Meier analysis and multivariate Cox regression analysis.
RESULTS: We identified advancing age, smoking history, alcohol consumption history, decreased forced expiratory volume in 1 s (FEV1), surgical procedure, tumor location, number of resected lymph nodes, poor tumor differentiation, and surgical stage as independent prognostic risk factors. Furthermore, based on the results of multivariate analysis, we constructed a novel scoring system that included the factors of age, smoking history, alcohol consumption history, number of resected lymph nodes, tumor differentiation, and surgical stage. Risk score (RS) was computed with the scoring system, and patients were divided into Class A (RS: 0-5) and Class B (RS: 6-10). P < 0.001 indicated statistical significance. A significant difference (p < 0.001) demonstrated that Class B was strongly related to a low survival rate and poor prognosis.
CONCLUSION: We developed a new simple flexible scoring system of high prognostic significance, which has the potential to guide postoperative therapeutic strategies and follow-up frequency and to provide better prognostic information for patients and their families.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Esophageal cancer; Esophageal surgery; Prognosis; Scoring system

Mesh:

Year:  2015        PMID: 25659876     DOI: 10.1016/j.ejso.2015.01.013

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  6 in total

1.  Recurrent laryngeal nerve lymph node dissection may not be suitable for all early stage esophageal squamous cell carcinoma patients: an 8-year experience.

Authors:  Shaobin Yu; Jihong Lin; Chenshu Chen; Jiangbo Lin; Ziyang Han; Wenwei Lin; Mingqiang Kang
Journal:  J Thorac Dis       Date:  2016-10       Impact factor: 2.895

2.  Prognostic value of MLH1 promoter methylation in male patients with esophageal squamous cell carcinoma.

Authors:  Dongping Wu; Xiaoying Chen; Yan Xu; Haiyong Wang; Guangmao Yu; Luping Jiang; Qingxiao Hong; Shiwei Duan
Journal:  Oncol Lett       Date:  2017-02-22       Impact factor: 2.967

3.  Genetic variants of DNA repair genes predict the survival of patients with esophageal squamous cell cancer receiving platinum-based adjuvant chemotherapy.

Authors:  Fei Zhou; Meiling Zhu; Mengyun Wang; Lixin Qiu; Lei Cheng; Ming Jia; Jiaqing Xiang; Qingyi Wei
Journal:  J Transl Med       Date:  2016-05-31       Impact factor: 5.531

4.  Modified nodal stage of esophageal cancer based on the evaluation of the hazard rate of the negative and positive lymph node.

Authors:  Jinling Zhang; Hongyan Li; Liangjian Zhou; Lianling Yu; Fengyuan Che; Xueyuan Heng
Journal:  BMC Cancer       Date:  2020-12-07       Impact factor: 4.430

5.  A novel prognostic model: which group of esophageal squamous cell carcinoma patients could benefit from adjuvant chemotherapy.

Authors:  Zihao Zhou; Shujie Huang; Xiaosong Ben; Weitao Zhuang; Liangli Hong; Zefeng Xie; Dongkun Zhang; Liang Xie; Haiyu Zhou; Jiming Tang; Gang Chen; Hansheng Wu; Guibin Qiao
Journal:  Ann Transl Med       Date:  2022-02

6.  Predictive Effects of Lung function test on Postoperative Pneumonia in Squamous Esophageal Cancer.

Authors:  Ran Wei; Wei Dong; Hongchang Shen; Yang Ni; Tiehong Zhang; Yibing Wang; Jiajun Du
Journal:  Sci Rep       Date:  2016-03-23       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.